Loading company…
SCBIO researches cancer-related diseases and develops anticancer drugs.
Daejeon-based SCBIO develops low-molecular compound immunotherapy drugs, including SCB001 and SCB002, which target immune cell activity in tumors. In August 2022, it raised KRW 6 billion in Pre-Series A funding, followed by KRW 11 billion in Series A funding in May 2023. The funding supports preclinical research and clinical development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in